In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is markedly enhanced with<unk>  versus mitoxantrone after prior docetaxel treatment. FIRSTANA (ClinicalTrials.gov identifier: NCT01308567) assessed whether<unk>  20 mg/m2 (C20) or 25 mg/m2 (C25) is superior to docetaxel 75 mg/m2 (D75) in terms of OS in patients with chemotherapy-naïve mCRPC. However, C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemotherapy-naïve mCRPC.<unk>  and docetaxel demonstrated different toxicity profiles, and C20 showed the overall lowest toxicity. In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving<unk>  versus 12.7 months for patients receiving mitoxantrone.<unk>  was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). Common adverse effects with<unk>  include neutropenia (including febrile neutropenia) and GIT side effects appeared mainly in diarrhea, whereas, neuropathy was rarely detected.
Cabazitaxel
Docetaxel
Paclitaxel
Doxorubicin
Ifosfamide
Lipoplatin
Bendamustine
Normustine